CloseHER2 Home: A feasibility study of a community pharmacy-led pathway for the administration of subcutaneous trastuzumab for HER2-positive breast cancer patients
Latest Information Update: 06 Jun 2024
At a glance
- Drugs Trastuzumab (Primary)
- Indications Breast cancer; HER2 positive breast cancer
- Focus Therapeutic Use
- Acronyms CloseHER2 Home
Most Recent Events
- 02 Jun 2024 Status changed from active, no longer recruiting to completed.
- 19 Jan 2023 Planned End Date changed from 30 Apr 2023 to 31 May 2024.
- 17 Jun 2022 New trial record